Last 12 months
Inside the activity.
0 purchase rows · 75 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 6 |
| Feb 2026 | 0 | 8 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 4 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 15 |
| Sep 2026 | 0 | 7 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 17,110 | $0.00 Strike: $63.91 | $0.00 |
DisclosureSEC source: 0001127602-21-010481 · form4.xml · derivative · entry 4 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,110 Underlying: Common Stock · 17,110 shares Expires 2031-03-10 F3 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010481 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,302 Underlying: Common Stock · 2,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Tax withholdingCommon Stock | 609 | $63.91 | $38,921.19 |
DisclosureSEC source: 0001127602-21-010481 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,825 Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionCommon Stock | 2,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010481 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010482 · form4.xml · derivative · entry 6 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,936 Underlying: Common Stock · 3,794 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F6 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC |
Dickinson Andrew DChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 16,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010482 · form4.xml · derivative · entry 5 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,730 Underlying: Common Stock · 16,430 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F3 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F5 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC |
Dickinson Andrew DChief Financial Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 95,620 | $63.91 Strike: $63.91 | $6,111,074.20 |
DisclosureSEC source: 0001127602-21-010482 · form4.xml · derivative · entry 4 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,620 Underlying: Common Stock · 95,620 shares Expires 2031-03-10 F4 · derivative.exercise_date: The options have a four year vesting schedule. 25% vest on the first anniversary date of the date grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC |
Dickinson Andrew DChief Financial Officer
|
Tax withholdingCommon Stock | 1,771 | $63.91 | $113,184.61 |
DisclosureSEC source: 0001127602-21-010482 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,930 Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:33 UTC |
Dickinson Andrew DChief Financial Officer
|
Exercise / conversionCommon Stock | 3,794 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010482 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:44 UTC |
Mercier JohannaChief Commercial Officer
|
GrantRestricted Stock Unit · Derivative | 15,845 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010484 · form4.xml · derivative · entry 5 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,435 Underlying: Common Stock · 15,845 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:44 UTC |
Mercier JohannaChief Commercial Officer
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 92,205 | $0.00 Strike: $63.91 | $0.00 |
DisclosureSEC source: 0001127602-21-010484 · form4.xml · derivative · entry 4 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,205 Underlying: Common Stock · 92,205 shares Expires 2031-03-10 F3 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:44 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010484 · form4.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,590 Underlying: Common Stock · 3,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:44 UTC |
Mercier JohannaChief Commercial Officer
|
Tax withholdingCommon Stock | 1,435 | $63.91 | $91,710.85 |
DisclosureSEC source: 0001127602-21-010484 · form4.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,564 Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 00:44 UTC |
Mercier JohannaChief Commercial Officer
|
Exercise / conversionCommon Stock | 3,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010484 · form4.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 02:59 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010492 · form4.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,856 Underlying: Common Stock · 10,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 02:59 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 307,355 | $63.91 Strike: $63.91 | $19,643,058.05 |
DisclosureSEC source: 0001127602-21-010492 · form4.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,355 Underlying: Common Stock · 307,355 shares Expires 2021-03-12 F4 · price: The options have a four-year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F3 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 02:59 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
GrantRestricted Stock Unit · Derivative | 52,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010492 · form4.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,656 Underlying: Common Stock · 52,810 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 02:59 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 5,123 | $63.91 | $327,410.93 |
DisclosureSEC source: 0001127602-21-010492 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,013 Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 02:59 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-010492 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2021 Filed Mar 31, 2021 22:53 UTC Amendment |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-012438 · form4a.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,856 Underlying: Common Stock · 10,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F4 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 31, 2021 22:53 UTC Amendment |
O'Day Daniel PatrickDirector · Chairman & CEO
|
GrantNon-qualified Stock Option (Right to Buy) · Derivative | 307,355 | $0.00 Strike: $63.91 | $0.00 |
DisclosureSEC source: 0001127602-21-012438 · form4a.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,355 Underlying: Common Stock · 307,355 shares Expires 2031-03-10 F3 · derivative.exercise_date: The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 31, 2021 22:53 UTC Amendment |
O'Day Daniel PatrickDirector · Chairman & CEO
|
GrantRestricted Stock Unit · Derivative | 52,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-012438 · form4a.xml · derivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,656 Underlying: Common Stock · 52,810 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2021 Filed Mar 31, 2021 22:53 UTC Amendment |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 5,123 | $63.91 | $327,410.93 |
DisclosureSEC source: 0001127602-21-012438 · form4a.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,013 Read SEC document |
| March 10, 2021 Filed Mar 31, 2021 22:53 UTC Amendment |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 10,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-012438 · form4a.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:46 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 11,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-009014 · form4.xml · derivative · entry 5 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,846 Underlying: Common Stock · 11,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F3 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:46 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 42,923 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-009014 · form4.xml · derivative · entry 4 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,209 Underlying: Common Stock · 42,923 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 1/3 vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 1/3 vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:46 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 24,620 | $62.46 | $1,537,765.20 |
DisclosureSEC source: 0001127602-21-009014 · form4.xml · nonDerivative · entry 3 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,336 Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:46 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 11,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-009014 · form4.xml · nonDerivative · entry 2 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:46 UTC |
O'Day Daniel PatrickDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 42,923 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-009014 · form4.xml · nonDerivative · entry 1 O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 15, 2021 Filed Mar 12, 2021 23:39 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
GrantCommon Stock | 334 | $56.86 | $18,990.07 |
DisclosureSEC source: 0001127602-21-010474 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,166 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2020 through February 15, 2021. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2021. Read SEC document |
| February 15, 2021 Filed Mar 12, 2021 23:42 UTC |
Parsey MerdadChief Medical Officer
|
GrantCommon Stock | 364 | $56.86 | $20,695.77 |
DisclosureSEC source: 0001127602-21-010476 · form4.xml · nonDerivative · entry 1 Parsey Merdad · CIK 0001792150 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,263 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2020 through February 15, 2021. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's stock on February 15, 2021. Read SEC document |
| February 15, 2021 Filed Mar 13, 2021 00:33 UTC |
Dickinson Andrew DChief Financial Officer
|
GrantCommon Stock | 364 | $56.86 | $20,695.77 |
DisclosureSEC source: 0001127602-21-010482 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,907 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2020 through February 15, 2021. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's stock on February 15, 2021. Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 22:56 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
SaleCommon Stock | 1,975 | $67.41 | $133,134.75 |
DisclosureSEC source: 0001127602-21-005277 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,832 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 22:58 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionRestricted Stock Unit · Derivative | 778 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-005279 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,327 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 22:58 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Tax withholdingCommon Stock | 197 | $67.29 | $13,256.13 |
DisclosureSEC source: 0001127602-21-005279 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,409 Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 22:58 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionCommon Stock | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-005279 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:41 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,818 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004786 · form4.xml · derivative · entry 3 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,300 Underlying: Common Stock · 1,818 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:41 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 538 | $68.46 | $36,831.48 |
DisclosureSEC source: 0001127602-21-004786 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,543 Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:41 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 1,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004786 · form4.xml · nonDerivative · entry 1 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:44 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,728 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004790 · form4.xml · derivative · entry 3 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,824 Underlying: Common Stock · 2,728 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:44 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Tax withholdingCommon Stock | 753 | $68.46 | $51,550.38 |
DisclosureSEC source: 0001127602-21-004790 · form4.xml · nonDerivative · entry 2 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,807 Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:44 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
Exercise / conversionCommon Stock | 2,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004790 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:46 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,866 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004792 · form4.xml · derivative · entry 3 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,105 Underlying: Common Stock · 1,866 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:46 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Tax withholdingCommon Stock | 533 | $68.46 | $36,489.18 |
DisclosureSEC source: 0001127602-21-004792 · form4.xml · nonDerivative · entry 2 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,828 Read SEC document |
| February 06, 2021 Filed Feb 10, 2021 00:46 UTC |
Wilfong Diane E.SVP, Controller & CAO
|
Exercise / conversionCommon Stock | 1,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004792 · form4.xml · nonDerivative · entry 1 Wilfong Diane E. · CIK 0001374988 · SVP, Controller & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:23 UTC |
Pletcher Brett AEVP,Corp Affairs & Gen Counsel
|
SaleCommon Stock | 9,711 | $65.97 | $640,632.73 |
DisclosureSEC source: 0001127602-21-003820 · form4.xml · nonDerivative · entry 1 Pletcher Brett A · CIK 0001739307 · EVP,Corp Affairs & Gen Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,832 F1 · kind: The sale transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan F2 · price: Sale prices reported for the transaction reported here range from $65.73 to $66.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 22:46 UTC |
Horning SandraDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-003029 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,936 Underlying: Common Stock · 632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on January 28, 2021. F2 · derivative.expiration_date: 100% of the restricted stock units vested on January 28, 2021. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 22:46 UTC |
Horning SandraDirector
|
Exercise / conversionCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-003029 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:45 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 878 | $66.70 | $58,562.60 |
DisclosureSEC source: 0001127602-21-002910 · form4.xml · nonDerivative · entry 3 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,263 Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:45 UTC |
Dickinson Andrew DEVP, Chief Financial Officer
|
GrantCommon Stock | 2,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002910 · form4.xml · nonDerivative · entry 2 Dickinson Andrew D · CIK 0001310204 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,141 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2018. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.